Shots:
- The US FDA has approved Bixlenvo (bictegravir 75mg/lenacapavir 50mg) for the treatment of HIV in adults who are virologically suppressed
- Approval was based on the P-III (ARTISTRY-1 & ARTISTRY-2) trials, assessing Bixlenvo (QD, PO) in adults with HIV who are virologically suppressed, incl. those who switched from complex multi-tablet regimens or from Biktarvy
- In both ARTISTRY-1 and ARTISTRY-2, Bixlenvo demonstrated comparable efficacy in maintaining virologic suppression at Wk. 48, with detailed results published in The Lancet and Lancet HIV, respectively
Ref: Businesswire | Image: Gilead | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
